The Nasdaq Biotechnology™ Index (NBI®) has been the leading benchmark for the biotech industry since its launch in 1993, reflecting Nasdaq’s historical dominance in attracting biotech IPOs ...

Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate ...